David H. Ilson

The 2018 Gastrointestinal Cancers Symposium

Investigators at the 2018 Gastrointestinal Cancers Symposium, held January 18–20 in San Francisco, reported key advances in GI cancer research. NEJM

Intensive Surveillance for Colorectal Cancer

How often to perform surveillance testing after curative treatment for patients with stage II–III colorectal cancer (CRC) remains controversial, as

Nivolumab for Esophageal Squamous-Cell Cancer

Treatment for metastatic esophageal squamous cancer mirrors treatment for metastatic gastric cancer, but beyond first-line fluorinated

Neoadjuvant Chemotherapy for Esophageal Adenocarcinoma

Standard preoperative therapy for esophageal adenocarcinoma is combined chemoradiotherapy followed by surgery. The use of preoperative chemotherapy

Reduced-Dose Sorafenib for Hepatocellular Cancer

Sorafenib, the only approved first-line therapy for hepatocellular cancer (HCC), has limited activity (mainly disease stabilization) and a modest

Cetuximab vs. Bevacizumab for KRAS Wild-Type Advanced Colorectal Cancer

Recent studies of KRAS wild-type advanced colorectal cancer (CRC) have reported mixed conclusions regarding the relative efficacy of bevacizumab versus

Cetuximab vs. Bevacizumab for

Recent studies of KRAS wild-type advanced colorectal cancer (CRC) have reported mixed conclusions regarding the relative efficacy of bevacizumab versus

Nivolumab for Metastatic MSI-High/dMMR Colorectal Cancer

Monoclonal antibodies targeting the PD-1 receptor and PDL-1 ligand typically have little or no activity in metastatic colorectal cancer (CRC). However,

Nivolumab for Chemotherapy-Refractory Gastric Cancer

First- and second-line chemotherapy are only modestly effective for patients with metastatic gastroesophageal adenocarcinoma, and new third-line

Cetuximab Ineffective for Esophageal Cancer

At least half of patients with unresectable or medically inoperable esophageal cancer achieve local control with definitive chemotherapy and radiation.